Coeptis Therapeutics (NASDAQ:ZSQR) Stock Price Up 14% – Here’s What Happened

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) rose 14% during trading on Monday . The stock traded as high as $10.68 and last traded at $10.61. Approximately 168,595 shares changed hands during mid-day trading, an increase of 88% from the average daily volume of 89,587 shares. The stock had previously closed at $9.31.

Coeptis Therapeutics Price Performance

The company has a 50 day moving average price of $11.95 and a 200 day moving average price of $13.26. The company has a market capitalization of $572.93 million, a price-to-earnings ratio of -4.42 and a beta of -0.22. The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $0.11 million during the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new position in shares of Coeptis Therapeutics in the 4th quarter worth $259,000. State Street Corp boosted its position in shares of Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after purchasing an additional 6,962 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after purchasing an additional 2,500 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after purchasing an additional 4,721 shares during the last quarter. Finally, Yorkville Advisors Global LP bought a new position in shares of Coeptis Therapeutics in the 3rd quarter worth $140,000. 13.88% of the stock is currently owned by institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.